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Abstract: Background: The tumor immune status “inflamed”, “immune excluded”, and “desert”
might serve as a predictive parameter. We studied these three cancer immune phenotypes while using
a simple immunohistochemical algorithm. Methods: Pre-treatment tissue samples of 280 patients
with locally advanced HNSCC treated with radiochemotherapy were analyzed. A double staining of
CD8+ cytotoxic T cells (CTL) and FoxP3+ (Treg) was performed and the cell density was evaluated in
the intraepithelial and stromal compartment of the tumor. Results: The classification of tumors as
“immune desert” when stromal CTL were ≤ 50 cells/mm2, “inflamed” when intraepithelial CTL were
> 500 cells/mm2, and as “excluded” when neither of these definitions met these cut off values allowed
the best discrimination regarding overall survival. These groups had median OS periods of 37, 61,
and 85 months, respectively. In “immune desert” and “immune excluded” tumors high Treg tended
to worsen OS, but in “inflamed” tumors high Treg clearly improved OS. Conclusions: We propose
that, in locally advanced HNSCC, the tumor immune state “inflamed”, “immune excluded”, and
“immune desert” can be defined by intraepithelial and stromal CTL. Tregs can further subdivide these
groups. The opposing effects of Tregs in the different groups might be the reason for the inconsistency
of Tregs prognostic values published earlier.
Keywords: CD8+; regulatory T cells; FoxP3+; head and neck squamous cell carcinoma; immune
dessert; inflamed; excluded
1. Introduction
Immune checkpoint inhibitors have exceptional anti-tumor activity in numerous cancer types [1]
and they play a central role in the quickly changing therapeutic landscape of medical oncology [2].
However, the response to checkpoint inhibition is limited to a subgroup of patients. In recurrent and/or
metastatic head and neck squamous cell cancer (HNSCC) PD-1 inhibitors have response rates of around
13% in unselected patients [3] and also only 19% after PD-L1 based patient selection (CPS score ≥ 1) [4].
As this is not satisfactory, there is great need to identify novel biomarkers with predictive significance.
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Checkpoint inhibitors activate cytotoxic immune cells, including CD8+ T cells, which, accordingly, are
potential predictors of tumor response [5].
A variety of immune markers exists that can be used to characterize the tumor immune status.
Besides immune cells, cell surface structures, cytokines, and tumor genetics or the microbiome may be
used [6]. In the context of immune checkpoint inhibitors, especially PD-L1, expressed on tumor cells
or immune cells were used to try to predict the responsiveness. More detailed analyses in HNSCC
patients focused on PD-L1 on CD8+ T cells [7]. In a recent review article, the variety of different
markers was grouped to three main immunological tumor subgroups, namely “immune desert”,
“immune excluded”, and “inflamed” cancers [6]. According to this classification, checkpoint inhibitors
are especially suited for the therapy of “inflamed” tumors. As a very complex pattern of properties
defines these subgroups, they are too complicated for response prediction in daily clinical routine.
Therefore, simpler strategies are needed to differentiate tumor groups. A promising and simple method
to differentiate groups could be the number of infiltrating CD8+ T lymphocytes (CTL), as one could
speculate that low CTL counts might impair the effectivity of checkpoint inhibition. Accordingly,
in a subgroup analysis of the Keynote-001 trial, it has been shown for non-small cell lung cancer
that patients with tumors having high intratumoural CD8 infiltration benefit from PD-1 blockade [8].
The same has previously been described for melanoma that is treated with PD-1 blockade [5]. Strongly
inflamed cancers might have particularly high antigenicity combined with a lack of effective immunity
due to suppressive mechanisms, so that checkpoint inhibition might be particularly successful in these
cases. Immunescape in tumors involves a variety of mechanisms, including the up-regulation of PD-L1,
CTLA-4, TIM-3, LAG-3, IL-10, TGF-β and the presence of M2-macrophages as well as regulatory T
cells (Treg), besides others. Treg are regularly observed at high frequencies in cancers [9–12]. Analysis
of prognostic significance of FoxP3+ Tregs has led to highly variable results between different cancer
types and, overall, a negative prognostic effect was associated with Tregs [13]. Thus, it appears to be
sensible to consider immunosuppressive FoxP3+ regulatory T cells in addition to immune-stimulating
CTL [13–15]. In HNSCC, there are contradictory results regarding the prognostic value of Treg [16].
In previous studies, we found no prognostic significance in low risk, high risk, and metastatic HNSCC
cohort [17,18]. Others reported a positive correlation of high Treg counts with either favorable [19–21]
or unfavorable prognosis [22–24]. To understand the reasons for such contradicting results would be
of great value to clarify immunological intratumoural mechanisms. We sub-grouped a large cohort
of patients with locally advanced HNSCC according to the number of infiltrating CD8+ cytotoxic T
lymphocytes in different compartments and analyzed the outcome in the thereby defined subgroups
in order to develop a simple algorithm to differentiate malignancies with different immune states.
Numbers of Treg were used to assess possible prognostic differences in these subgroups.
2. Results
2.1. Distribution and Prognostic Value of CTL and Treg
The distribution of the CTL and Treg in the tumor was measured as cell density both in the
stromal and intraepithelial compartment of the tumor (Figure 1A–C). CTL had a median density of
306.5 cells mm−2 in the stromal compartment and 235.5 cells mm−2 in the intraepithelial compartment.
According values for FoxP3+ cells were 145.1 and 52.7 cells mm−2, respectively (Figure 1D). CTL were
1.3 times more frequent in the stromal than in the intraepithelial compartment (Figure 1E). FoxP3+ cells
were 3.1 times more frequent in the stromal than the intraepithelial compartment. The CTL cells were
4.6 times and 2.0 times more frequent than FoxP3+ cells in the intraepithelial and stromal compartment,
respectively (Figure 1F).
For both markers, the median rate of lymphocytes per mm2 was used as cut off to separate two
groups. The overall survival curve for patients with high CTL counts lay above the curve for patients
with low CTL counts both with regard to the epithelial (p = 0.184) and the stromal compartment
(p = 0.101), but it did not reach statistical significance (Figure 1G,H). In the stromal compartment, high
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FoxP3+ rates were clearly linked with improved overall survival (p = 0.001) (Figure 1J), whereas in the
intraepithelial compartment, FoxP3+ cells had no influence on outcome (p = 0.694) (Figure 1K).Cancers 2019, 11, 3 of 13 
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the largest (n = 150/53.6%) and it had an intermediate survival of 61 month. The “inflamed” group (n 
= 77/27.5%) tended to have favorable overall survival of 85 month (p = 0.054) (Figure 2A). Cases in the 
unfavorable “immune desert” group presented with larger tumor sizes (p < 0.001) as compared to the 
other two groups (Figure 2B) and fewer p16 positive cancers when compared to the “inflamed” 
tumors (p = 0.007) (Figure 2C). There tended to be higher tumor grades in the “inflamed” group, 
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Figure 1. CD8+ and FoxP3+ cell densities in head and neck cancer. Kaplan Meier plots for metastasis
free rate, recurrence free rate and overall survival in the complete cohort of 280 patients (A). Tissue
samples were processed into tissue microarrays using a core diameter of 2 mm. Scale bar 200 µm
(B). High power views (1:400) with immunohistochemical double staining for FoxP3 (red nucleic
staining) and CD8 (blue predominantly membranous staining). (Scale bars 10 µm) (C). Lymphocyte
densities (cells/mm2) in the intraepithelial and stromal compartment were separately analyzed (D).
Stromal/intraepithelial ratio of CD8+ and FoxP3+ cells (E). CD8+/FoxP3+ ratio in intraepithelial and
stromal compartment (F). Kaplan Meier plots for densities of CD8+ lymphocytes in the stromal (G)
and intraepithelial H as well as FoxP3+ cells in the stromal (J) and epithelial (K) compartment (overall
survival). Cut-off values were the median.
2.2. ro ti l f I esert”, “I une Excluded” and “Inflamed Tumors”
e subseq e tl efi e t ree s roups to stratify the tumors better for overall sur ival
analyses. Tu ors ere divided into three subgroups, namely “i mune desert”, “i mune excluded”,
and “inflamed” cases in order to recapitulate a proposed model of different immunological backgrounds
in cancer [6]. We defined two cut off points, including less or equal 50 CTL per mm2 in the stromal
compartment and more than 500 CTL per mm2 in the intraepithelial compartment, as mentioned above.
Cases with less or equal 50 CTL in the stroma were included in the “immune desert” group, those
with over 500 intraepithelial CTLs in the “inflamed” group. All of the cases meeting neither of the
two definitions were included in the “immune excluded” group. Patients meeting “immune desert”
criteria comprised the smallest group (n = 53/18.9%) and had an unfavorable prognosis with a median
survival of 37.0 month. The “immune excluded” group was the largest (n = 150/53.6%) and it had
an intermediate survival of 61 month. The “inflamed” group (n = 77/27.5%) tended to have favorable
overall survival of 85 month (p = 0.054) (Figure 2A). Cases in the unfavorable “immune desert” group
presented with larger tumor sizes (p < 0.001) as compared to the other two groups (Figure 2B) and
fewer p16 positive cancers when compared to the “inflamed” tumors (p = 0.007) (Figure 2C). There
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tended to be higher tumor grades in the “inflamed” group, which did not reach statistical significance
(p = 0.121) (Figure 2D). No differences between the groups were observed regarding sex, age, location,
presence of affected regional lymph nodes or distant metastasis (Figure S1A–E). Cancer treatment
differed between the groups with higher rates of definite radio-chemotherapeutic treatment in patients
in the “desert” group (Figure S1F).
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Figure 2. Subgroups “i une desert”, “i une excluded” and “infla ed”. “I une desert” as
efi e as avi g 50 8 cells/ i t e stro al co art e t, “i e excl e ” 500 8
cells in the intraepithelial and > 50 in the stromal compartment and “inflamed” having > 500 cells in the
intraepithelial compartment. Kaplan Meier plots for overall survival in these groups (A) Tumor size (B)
p16 staining (C) and tumor grade (D) were compared. Kaplan-Meier plots for the FoxP3+ cell densities
in the stromal and intraepithelial compartment in the “immune desert” group (E,F), in the “immune
excluded” group (G,H), and the “inflamed” group (J,K) Cut-off values were median FoxP3+ densities.
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In addition, we used the median value of FoxP3+ cells per mm2 to further subdivide the three
earlier defined groups, in order to better understand the significance of FoxP3+ Treg. Tregs were
separated into high and low at the median of each group. In the “desert” group numbers of Tregs had
no influence on prognosis (p = 0.559) in the stromal compartment. In the intraepithelial compartment,
the overall survival curve of patients with high Treg counts lay below the curve of patients with
low Treg counts, without reaching statistical significance (p = 0.174) (Figure 2E,F). In the “immune
excluded” group, low amounts of Tregs in the stromal compartment (p = 0.104) and high amounts
of Treg in the intraepithelial compartment seemed to be unfavorable (p = 0.100), both not reaching
statistical significance (Figure 2G,H). In the “inflamed” group, high amounts of Tregs were associated
with improved survival both in the stromal and in the intraepithelial compartment, (p = 0.066 and
p = 0.008, respectively).
2.3. Characteristics of “Immune Desert”, “Immune Excluded”, and “Inflamed Tumors”
Next, we studied the relative distribution of Tregs and CTL in the three groups defined by CTL
infiltration. In the “desert” group, which is defined by low stromal CTL counts, both intraepithelial
and stromal Tregs and CTL counts were low (Figure 3A). In the “immune excluded” group, stromal
CTL and Tregs were increased to an equal extent, whereas in the intraepithelial compartment, both cell
types were still quite low (Figure 3B). In the “inflamed” group, defined by high intraepithelial CTL,
both in the intraepithelial and in the stromal compartment, CTL and Tregs were increased (Figure 3C).
with the proportion of CTL being even higher than of Treg, in both compartments.
Tumor and epidemiologic characteristics of the groups defined by CTL and Treg infiltration
were subsequently analyzed. In the “inflamed” group, low stromal Treg counts were associated with
larger tumor size (p < 0.001) and more lymph node metastases (p = 0.039) (Figure 3D,E). Additionally,
higher Treg counts in the “desert” group were linked to more undifferentiated cancers, as indicated by
the tumor grading (p = 0.018) (Figure 3F). Some slight differences were observed with regard to the
remaining parameters (Figure S2) without reaching significance.
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3. Discussion
We studied the tumor samples of 280 head and neck cancer patients double stained for CD8+
and FoxP3+ T lymphocytes. First, we used the median as cut-off to separate patient groups with
low and high numbers of lymphocytes quantified both in the epithelial and stromal compartment
separately. As expected, in the stromal as well as intraepithelial compartment high numbers of CTLs
were associated with improved OS. This confirmed the findings of several earlier studies [17,25,26].
CTLs are able to kill infected, neoplastic, or otherwise targeted cells by direct lysis, and thereby are the
most powerful anticancer mediators of the immune system [27]. However, CTLs can only effectively
destroy tumor cells if they can proliferate, mature, and are not inhibited in their functions by other
factors. In this process, Tregs are one of the key players. They act as suppressors of inflammatory
and anti-tumoral response, and thus maintain immunological tolerance to host tissues [13] and can
potentially promote tumor growth. Thus it is not surprising that Tregs were often associated with
an unfavorable outcome in malignancies, including HNSCC [24,28]. However, other studies exist that,
in contrary, found an association of high numbers of Tregs and a favorable outcome [9,19]. This positive
impact of FoxP3+ Tregs might be partially attributed to the down-regulation of a persistent inflammatory
process, which could promote inflammation-driven tumor progression [13]. In the present study, high
numbers of Tregs in the stromal compartment were clearly associated with an improved OS (p = 0.001).
Astonishingly, intraepithelial Tregs had no impact on OS (p = 0.694), going in line with earlier findings
in a rectal cancer cohort with 103 patients [29]. So far, it remained unclear why such powerful immune
suppressors as FoxP3+ Tregs, which are located in the critical intraepithelial area, have no impact on
survival. It has to be mentioned that Tregs were solely detected by the positivity of the FoxP3 staining
and no additional markers as CD4 and CD25 were used. These three markers are typically used in
flow cytometric assays [30]. However, FoxP3 appears to be the best single marker for Treg [31].
To figure out why there are such contrary effects, we decided to focus on the distribution of CTLs.
Cancers were classified in only two groups by low or high amounts of tumor infiltrating inflammatory
cells may not appropriately address the problem. Recently, three groups of inflammatory states in
tumor microenvironment were described, defined by the frequency and properties of infiltrating
cells [6]. We used an approach to appropriately define these groups by the frequency of CD8+ cells as
a surrogate marker. These groups were called “immune desert”, with nearly no immune cell infiltration,
“immune excluded” in which the immune cells are concentrated at the stromal-epithelial boundaries
with low intraepithelial counts and “inflamed”, in which the immune cells infiltrate the epithelial
compartment and strong inflammation is present. Here, we used more than 500 intraepithelial CTLs
mm−2 to define the “inflamed” group, less or equal 50 CTL stromal cells mm−2 to define the “desert”
group and included all cases not meeting one of the above-mentioned criteria in the “immune excluded”
group. These thresholds for the three groups were fitted for the present cohort and they must be
verified in future studies. However, it demonstrates that the three groups can be differentiated that
have different prognostic parameters.
The survival plots of the “immune desert”, “immune excluded”, and “inflamed” group were
further subdivided according to the numbers of infiltrating FoxP3+ Tregs. The most striking finding
was that intraepithelial Tregs gained prognostic relevance when analyzing the subgroups in contrast to
the whole cohort and that the prognostic value of Tregs is largely dependent on the state of inflammation
of the tumor. In the “immune desert” and “immune excluded” group, higher intraepithelial Tregs than
the median tended to worsen overall survival. This is in accordance with the classical assumption
that immunosuppressive Treg are associated with a worse prognosis of patients by suppressing
anti-tumoural immunity [32]. In contrast, in “inflamed” tumors, high Tregs were associated with
significantly better overall survival, probably due to the down-regulation of harmful inflammatory
reaction, which could favor tumor progression, as inflammation can induce tumorigenesis [9].
As the unfavorable effect in the “desert” and “excluded” groups and the favorable effect in the
“inflamed” group opposed each other in the undivided group, those effects were obscured when
analyzing the complete cohort divided at the median of CTL counts. This finding might be the key
Cancers 2019, 11, 1398 8 of 13
to explaining the differing findings of the prognostic value of Treg in different published analyses
mentioned above. Our cohort consists of different primary tumor sites, stages, and includes different
therapy regimens that result in a cohort with different states of inflammation. If uniform groups
are studied, the states of inflammation might be more consistent and result in either favorable or
unfavorable prognoses.
Especially in “immune excluded” tumors, the prognostic effect of Tregs differed when comparing
the stromal and intraepithelial compartment. High Treg counts improved prognosis in the stromal
compartment, but worsened it in the intraepithelial compartment. The reason might be that the
accumulation of immune cells plays different mechanistic roles in the stromal and intraepithelial
compartment of the tumor. In the stroma, both endothelia and fibroblasts and their surface markers
are important in the recruitment of inflammatory cells [6,33]. Moreover, the extracellular matrix,
especially collagens and fibronectin, are playing an essential role. The main difference to intraepithelial
inflammation is probably that no direct interaction of tumor cells and inflammatory cells takes place
and the chemokine concentrations are lower. In intraepithelial recruitment, the tumor cell chemokines
that are produced by tumor cells are higher concentrated and direct cell-to-cell, receptor mediated
interactions are possible. Thus, it can be speculated that intratumoural CTL more frequently have
anti-tumoural properties than stromal CTL. This could explain why Tregs inhibiting intratumoural
(mostly anti-tumoural directed) CTL worsen prognosis and Tregs inhibiting stromal CTL (unspecific
inflammation) improve prognosis by the reduction of growth factors and cytokines [9].
The results of simultaneous FoxP3-staining indicate that the very simple classification that is based
on CTLs alone might not suffice to define groups predicting response to cancer therapies. Analysis with
regard to the numbers of Tregs indicated that both the “excluded” and the “inflamed” groups were not
homogenous, but that they can be further stratified according to FoxP3+ Treg cell counts, underlining
an important immune modulatory role of Tregs in the tumor microenvironment. Hence, one could
postulate that in the different subgroups the success of checkpoint inhibition might be influenced
by the amounts of Tregs. Accordingly, murine models resistance to PD-1/PD-L1 pathway blockade
is frequently mediated by Treg [34,35]. Thus, inflamed tumors with low intraepithelial Tregs might
probably respond best to the immune checkpoint blockade. However it is possible that checkpoint
inhibitors can restore CTL activity, even in the “immune desert” and “immune excluded” group with
low Treg.
Plentiful data exists reporting improved treatment response to immune checkpoint inhibitors in
inflamed tumors when compared to not-inflamed tumors [6]. Our findings indicate that it is probably
insufficient to select cancer patients for checkpoint inhibitor therapy by CTL counts or degree of
inflammation alone. A variety of mechanisms are probably determining tumor response to checkpoint
inhibition due to the complexity of the interplay of immunocytotoxicity and immunosuppression.
The subgrouping by Treg possibly improves the selection of patients that will benefit from checkpoint
inhibition, but still will not represent the whole story. Prospective studies using checkpoint
inhibitors are needed to develop an immunohistochemical algorithm beyond PD-L1 stainings to
select possible responders.
4. Materials and Methods
4.1. Patient Cohort
Tumor tissues of 280 patients that suffer from locally advanced HNSCC treated at the University
Hospital Erlangen between 1992 and 2010 were collected [17,18,36]. Clinical data were obtained from
the Erlangen Tumour Centre Database and patient records. Written informed consent was obtained
‘front door’ from all patients allowing for the collection of their tissue and clinical data. The use of
formalin fixed paraffin-embedded material from the Archive of the Institute of Pathology was approved
by the Ethics Committee of the Friedrich-Alexander-University of Erlangen-Nuremberg on 24 January
2005, waiving the need for consent for using the existing archived material. Table 1 gives clinical and
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histological characteristics of the patient cohort. 51 patients received a definitive radiochemotherapy
(RCT), 196 were treated with surgery and adjuvant RCT, and 33 with a neoadjuvant RCT followed by
surgery. In the subgroup that was treated with adjuvant RCT, 173 patients (88.3%) had no residual
tumor, 21 patients (10.7%) had microscopic, and 2 (1.0%) macroscopic residual tumor. All of the
patients were in first line treatment and all tissue samples were obtained prior to RCT. The median
follow-up was 44 months. Most of the patients were male (82.9%) with a median age of 55 years.
All T-stages were common; most patients had N2 lymph node status (58.6%). Overall survival was
51.2% after five years. The distant metastases free rate was 72.4% and the local recurrence free rate was
76.3% after five years (Figure 1A).
Table 1. Clinical characteristics of 280 head and neck cancer patients.
Clinical Characteristics Number of Patients (Percentage)
Sex Male: 232 (82.9%), female: 48 (17.1%)
Age (years) mean: 55 ± 9, min.: 27 max.: 81
Primary Tumor T1: 52 (18.6%), T2: 85 (30.4%), T3: 73 (26.1%), T4: 70 (25%)
Regional Lymph Nodes N0: 53 (18.9%), N1: 40 (14.3%), N2: 164 (58.6%), N3: 23 (8.2%)
Distant Metastasis M0: 276 (98.6%), M1: 4 (1.4%)
UICC Stage I 10 (3.6%), II 26 (9.3%), III 51 (18.2%), IV 193 (68.9%)
Grading G1: 15 (5.4%), G2: 165 (58.9%), G3: 91 (32.5%) G4: 9 (3.2%)
p16 negative: 170 (60.7%), positive: 49 (17.5%), unknown: 61 (21.8%)
Treatment definitive RCT: 51 (18.2%), adjuvant RCT: 196 (70%), neoadjuvant RCT: 33 (11.8%)
R classification (Adjuvant RCT) R0: 173 (88.3%) R1: 21 (10.7%) R2: 2 (1.0%)
4.2. Immunohistochemistry
Formalin-fixed paraffin-embedded tissue specimens were processed in tissue microarrays with cores
of 2 mm diameter (Figure 1B). CD8+ antibodies were used to identify cytotoxic T lymphocytes (CTL, blue
membranous staining) and FoxP3 antibodies to identify regulatory T cells (Treg, red nuclear staining).
Immunohistochemistry was performed as double staining (Figure 1C) while using a CD8-specific
antibody (M7103, Agilent, Santa Clara, CA, USA) and a FoxP3-specific antibody (Ab20034, abcam,
Cambridge, United Kingdom). For detection, a Polymer-Kit and Fast Red and Polymer-Kit and Fast
Blue (POLAP-100 Zytomed Systems, Berlin, Germany) were used according to the manufacturer’s
instructions [37,38]. A microscopic scanner (Imager Z2, Zeiss, Göttingen, Germany), combined with
a Metafer software (Metasystems, Altlussheim, Germany), was used to scan the stained TMAs at
a magnification of 400 times. The cells were counted applying the image analysis software (Biomas
Software, Version 3.3; MSAB, Erlangen, Germany) [39]. The stromal and the epithelial compartment
were both analyzed separately and positive cells per mm2 were quantified.
4.3. Determining the Cut of Values for “Immune Desert”, “Immune Excluded” and “Inflamed Tumors”
In a recent review article, three main immunological phenotypes of cancer have been described:
“immune desert”, “immune excluded”, and “inflamed” [6]. The aim of the current analysis was to
classify tumors in these three groups that were based on intratumoral CTL and Treg. For determining
the cut of values, first we decided that “immune desert” tumors should be defined by stromal and
“inflamed” tumors by intraepithelial CTL. Randomly, the “immune desert” group was defined as
< 10 CTL mm−2 stroma and the “inflamed” group as > 1000 CTL mm−2 in the epithelium and the
“immune excluded” group as not meeting either parameter. Kaplan Meier plots for overall survival
were used to find a possible difference between the “immune desert” and “immune excluded” by
changing the threshold in steps of 10 CTL. After finding a clear difference (p < 0.010), we subsequently
repeated this approach comparing “immune excluded” and “inflamed” groups while using steps of
50 CTL. The cut of values that were found by this procedure were used in a second round repeating the
same procedure, which resulted in cut of values of ≤ 50 cells mm−2 in the stromal and > 500 cells mm−2
in the epithelial compartment as the best discriminative values regarding overall survival.
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4.4. Statistical Analysis
Statistical analysis was performed while using SPSS version 21 (IBM Inc., Chicago, IL, USA).
Overall survival (OS) was analyzed with the Kaplan Meier method. The log-rank test was used to
compare the survival curves between the subgroups of the patient cohort. The comparison of the
characteristics of the different immunological groups was done with the Student’s t-test.
5. Conclusions
In conclusion, the present head and neck cancer cohort can be divided in at least three different
subgroups, which might overlap with the earlier described phenotypes of “immune desert”, “immune
excluded”, and “inflamed” tumors. Useful cutoff values may be ≤ 50 stromal and > 500 intraepithelial
CTLs mm−2. These cut off values must be validated in future studies. Treg counts can further subdivide
these groups and indicate that there is still heterogeneity in the groups. The different prognostic
findings for Tregs in the subdivided groups might explain the contradictory results of previously
published studies regarding the prognostic significance of Treg.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/9/1398/s1,
Figure S1: “Immune desert” was defined as having ≤ 50 CD8+ cells in the stromal compartment, “immune
excluded” < 500 CD8+ cells in the intraepithelial and for > 50 in the stromal compartment and “inflamed” as
having > 500 cells in the intraepithelial compartment. Clinical characteristics regarding sex (A), age (B), tumor
location (C), regional lymph node metastases (D), distant metastases (E) and treatment modalities (F) in the three
subgroups, Figure S2: FoxP3+ lymphocyte densities (cells/mm2) in the intraepithelial and stromal compartment of
the “immune desert”, “immune excluded” and “inflamed” groups, according to tumor and patients parameters
including, sex (A), age (B), tumor location (C), treatment modalities (D), p16 staining (E) and distant metastases
(F). Cut-off values were the median FoxP3+ densities.
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